🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hemophilia B
Clinical trial register · United States · industry-sponsored

Hemophilia B Trials in the USA

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9109 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 20 Sep 2026, 03:16 UTC
9109
Studies in scope
industry-sponsored, all four open statuses
4946
Recruiting now
open to new participants
2196
Lead sponsors
across recruiting studies
Top states
California 8 Michigan 6 Colorado 5 Pennsylvania 5 Florida 5
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
CSL Behring4 Pfizer4 Regeneron Pharmaceuticals2 Baxalta now part of Shire1 Equilibra Bioscience LLC1
State
California8 Michigan6 Colorado5 Pennsylvania5 Florida5
All 26 states
Target enrolment
to
12 of 9109 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
NCT07080905Hemophilia B
CSL Behring
Phase 3
20
California, Florida, Georgia, Michigan, Tennessee
2025-07-28
Recruiting
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
NCT06379789Hemophilia B
Regeneron Pharmaceuticals
Phase 1/2
130
California, Colorado, Connecticut, Florida, Indiana, Louisiana, Michigan, Ohio
2024-09-11
Recruiting
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
NCT06349473Healthy Participants, Hemophilia A, Hemophilia B, Factor VII Deficiency
Equilibra Bioscience LLC
Phase 1
31
California, Illinois, Louisiana, Michigan, Missouri, North Carolina, Pennsylvania
2024-05-10
Recruiting
Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
NCT06003387Hemophilia B
CSL Behring
Phase 3
35
California, Michigan, Pennsylvania, Texas
2024-01-30
Active, closed
A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy
NCT05568459Hemophilia B
Regeneron Pharmaceuticals
Observational
11
Colorado, Connecticut, District of Columbia, Florida, Illinois, Indiana, Michigan, Ohio
2024-01-17
By invitation
Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)
NCT05962398Hemophilia B
CSL Behring
Observational
56
Arizona, Arkansas, California, Colorado, Florida, Michigan, North Carolina, Oregon
2023-08-30
Recruiting
An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B
NCT06008938Hemophilia B
CSL Behring
Observational
500
New York
2023-06-15
Recruiting
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
NCT05568719Hemophilia A, Hemophilia B
Pfizer
Phase 3
173
California, Florida, Mississippi, New York, Pennsylvania, Washington
2022-12-28
Recruiting
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
NCT05611801Hemophilia A, Hemophilia B
Pfizer
Phase 3
100
Utah
2022-12-09
Recruiting
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
NCT05145127Hemophilia A, Hemophilia B
Pfizer
Phase 3
245
Iowa, New York, Pennsylvania, Washington
2021-11-17
Active, closed
A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B
NCT03861273Hemophilia B
Pfizer
Phase 3
51
California, Colorado, Indiana, Mississippi, Pennsylvania
2019-07-29
Active, closed
Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B
NCT01687608Hemophilia B
Baxalta now part of Shire
Phase 1/2
30
California, Colorado, Georgia, Illinois, Massachusetts, Minnesota, New York, Oregon
2013-02-11
Rows per page Showing 1–12 of 12
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-usa/condition/hemophilia-b

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.